Genmab applies Seattle's ADC platform to anti-TF antibody
Seattle Genetics Inc. has licensed its antibody-drug conjugate (ADC) technology to cancer MAb developer Genmab AS, which will apply the platform to its preclinical HuMax-TF candidate.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com